EMERYVILLE, Calif.–(BUSINESS WIRE)– #biotech–Fauna Bio announces first candidate nomination of Faun1083 for the treatment of heart failure.

TORONTO–(BUSINESS WIRE)–Breast Cancer Canada is committed to its mission to advance breast cancer research, advocacy, and equitable access in 2025.

FARMINGTON, Conn.–(BUSINESS WIRE)–Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to Onkos Surgical (“Onkos”), of which $30 million h

BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 20

SAN DIEGO–(BUSINESS WIRE)–Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a first-in-human trial with NVI-100, the company’s lead investigational drug for the acute treatment of migraine. NVI-100 is a first-in-class water-soluble peptide antagonist for the calcitonin gene-related peptide (CGRP) receptor delivered via a patient-friendly autoinjector for

BOSTON–(BUSINESS WIRE)–AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement with the University of Missouri-Columbia to work with Dr. Carolyn Anderson, Simón-Ellebracht Professor in Medicinal Chemistry and Professor of Radiology, and her team to jointly pursue specific research projects to advance the use of de novo designed miniproteins for targe

MIAMI–(BUSINESS WIRE)–Ontrak, Inc (NASDAQ: OTRK), (“Ontrak” or the “Company”), an AI-powered and telehealth-enabled behavioral healthcare company, announced it has signed an agreement to provide its behavioral health solutions to Intermountain Health’s Medicare Advantage members in Nevada. Intermountain Health is a prominent healthcare system operating 400 clinics and 34 hospitals in the western United States. Intermountain Health is known for its high quality, affordable and personalized car

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis